| Trial ID: | L6759 |
| Source ID: | NCT04485845
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Metabolic Syndrome|Diabete Type 2|Kidney Insufficiency
|
| Interventions: |
DRUG: Vildagliptin|DRUG: Captopril Tablets|DRUG: MetFORMIN 500 Mg Oral Tablet
|
| Outcome Measures: |
Primary: progression of metabolic syndrome complications, investigate the effect of antidiabetic drugs on improving patients' cases and reduce complcations of metablic syndrome and that will be assessed by measuring glucose serum levels, insulin plasma levels to calculate insulin resistance by HOMA-ir, 24 weeks|estimation of metabolic syndrome deterioration, study the effect of both antidiabetic drugs on blood pressure, 24 weeks | Secondary: reduce nephropathic impairement, study the impact of both metformin and vildagliptin on reducing kidney deterioration for patients suffering from metabolic syndrome and that can be assessed by measuring kidney function serologically using ELISA kits for each parameter, 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Cairo University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-11-01
|
| Completion Date: |
2020-09-30
|
| Results First Posted: |
|
| Last Update Posted: |
2020-07-24
|
| Locations: |
National Diabetes & Endocrinology Institute, Cairo, 11311, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04485845
|
